The drug Mavorixafor was previously granted the Fast Track designation for the treatment of WHIM syndrome, a rare immunodeficiency indication for which it received FDA approval in April 2024, X4 said.

Welcome to Indie App Spotlight. This is a weekly 9to5Mac series where we showcase the latest apps in the indie ...

Health trackers keep tabs on nearly 1 in 4 Americans at this point. Professor of Medicine Sandeep Kishore, MD, PhD, MSc, ...

The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat ...

RTX carries a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $5.2 billion in cash on hand, and ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

President Donald Trump said his executive order on drug prices would lower some prices in half or more. But the details are ...